company background image

Inhibrx NasdaqGM:INBX Stock Report

Last Price


Market Cap







10 Aug, 2022


Company Financials +
INBX fundamental analysis
Snowflake Score
Future Growth2/6
Past Performance0/6
Financial Health2/6

INBX Stock Overview

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates.

Inhibrx, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Inhibrx
Historical stock prices
Current Share PriceUS$23.60
52 Week HighUS$47.90
52 Week LowUS$7.67
1 Month Change48.15%
3 Month Change61.87%
1 Year Change-24.21%
3 Year Changen/a
5 Year Changen/a
Change since IPO14.40%

Recent News & Updates

Jun 10

Inhibrx: Potential To Move To Registration Study With INBRX-101

Positive results have been released thus far from a phase 1 study using INBRX-101 for the treatment of patients with Alpha-1 Antitrypsin Deficiency. It is expected that the Alpha-1 Antitrypsin Deficiency Augmentation therapy market could reach $1.95 billion by 2026. If FDA gives green light to Inhibrx, then it should be able to initiate a pivotal registration study using INBRX-101 for patients with Alpha-1 Antitrypsin Deficiency 2nd half of 2022. INBRX-109, INBRX-106, INBRX-105, and INBRX-121 are 4 additional drugs in the pipeline being advanced as treatments for cancer; All 4 of these drugs plus INBRX-101 utilize the company's Single-domain antibody technology platform.

Shareholder Returns

INBXUS BiotechsUS Market

Return vs Industry: INBX exceeded the US Biotechs industry which returned -25.9% over the past year.

Return vs Market: INBX underperformed the US Market which returned -13.5% over the past year.

Price Volatility

Is INBX's price volatile compared to industry and market?
INBX volatility
INBX Average Weekly Movement17.0%
Biotechs Industry Average Movement12.8%
Market Average Movement7.9%
10% most volatile stocks in US Market17.2%
10% least volatile stocks in US Market3.2%

Stable Share Price: INBX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 17% a week.

Volatility Over Time: INBX's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

2010109Mark Lappe

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company’s therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications.

Inhibrx, Inc. Fundamentals Summary

How do Inhibrx's earnings and revenue compare to its market cap?
INBX fundamental statistics
Market CapUS$921.76m
Earnings (TTM)-US$110.75m
Revenue (TTM)US$7.03m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
INBX income statement (TTM)
Cost of RevenueUS$91.90m
Gross Profit-US$84.87m
Other ExpensesUS$25.88m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)-2.84
Gross Margin-1,207.64%
Net Profit Margin-1,575.91%
Debt/Equity Ratio-3,449.8%

How did INBX perform over the long term?

See historical performance and comparison